Skip to main content

Table 1 Enriched signatures from the Broad canonical pathway library among outlier genes

From: Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

Canonical pathway signature # of outlier genes in the signature P(enrichment) FDR
KEGG_PATHWAYS_IN_CANCER 17 1.53E-07 1.63E-04
KEGG_PROSTATE_CANCER 10 2.46E-07 1.63E-04
KEGG_THYROID_CANCER 6 5.01E-06 2.22E-03
PID_WNT_CANONICAL_PATHWAY 4 1.05E-05 3.25E-03
KEGG_ENDOMETRIAL_CANCER 7 1.22E-05 3.25E-03
PID_BETACATENIN_DEG_PATHWAY 4 3.65E-05 7.14E-03
KEGG_MELANOMA 7 3.76E-05 7.14E-03
KEGG_GLIOMA 7 4.44E-05 7.38E-03
REACTOME_CELL_CYCLE_MITOTIC 12 5.20E-05 7.68E-03
KEGG_BLADDER_CANCER 5 1.10E-04 1.47E-02
KEGG_NON_SMALL_CELL_LUNG_CANCER 6 1.56E-04 1.88E-02
PID_HES_HEYPATHWAY 5 1.76E-04 1.88E-02
KEGG_COLORECTAL_CANCER 6 1.84E-04 1.88E-02
REACTOME_SIGNALING_BY_FGFR 7 2.12E-04 2.02E-02
KEGG_ACUTE_MYELOID_LEUKEMIA 6 2.90E-04 2.41E-02
PID_SMAD2_3NUCLEARPATHWAY 6 3.35E-04 2.47E-02
ST_WNT_BETA_CATENIN_PATHWAY 4 3.53E-04 2.47E-02
BIOCARTA_GSK3_PATHWAY 4 3.53E-04 2.47E-02
REACTOME_MITOTIC_G2_G2_M_PHASES 5 3.90E-04 2.60E-02
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 7 4.24E-04 2.68E-02
PID_MTOR_4PATHWAY 6 5.70E-04 3.29E-02
BIOCARTA_G1_PATHWAY 4 5.94E-04 3.29E-02
SA_G1_AND_S_PHASES 3 6.95E-04 3.29E-02
REACTOME_G0_AND_EARLY_G1 3 6.95E-04 3.29E-02
PID_TCRRASPATHWAY 3 6.95E-04 3.29E-02
PID_RB_1PATHWAY 6 7.27E-04 3.29E-02
PID_IL4_2PATHWAY 5 7.61E-04 3.29E-02
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE 7 7.77E-04 3.29E-02
KEGG_RENAL_CELL_CARCINOMA 6 8.17E-04 3.29E-02
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR 6 8.17E-04 3.29E-02
REACTOME_CELL_CYCLE 12 9.15E-04 3.54E-02
REACTOME_SIGNALING_BY_ERBB2 6 1.27E-03 4.21E-02
KEGG_CHRONIC_MYELOID_LEUKEMIA 6 1.27E-03 4.21E-02
BIOCARTA_CELLCYCLE_PATHWAY 3 1.44E-03 4.55E-02
PID_FOXM1PATHWAY 4 1.66E-03 4.96E-02
REACTOME_SIGNALING_BY_PDGF 6 1.89E-03 4.96E-02
REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS 3 1.94E-03 4.96E-02
PID_E2F_PATHWAY 5 1.97E-03 4.96E-02
PID_ER_NONGENOMIC_PATHWAY 4 1.98E-03 4.96E-02
REACTOME_SIGNALING_BY_EGFR_IN_CANCER 6 2.07E-03 5.10E-02
BIOCARTA_P53_PATHWAY 3 2.55E-03 5.84E-02
KEGG_PANCREATIC_CANCER 5 2.77E-03 6.14E-02
PID_PI3KPLCTRKPATHWAY 4 3.64E-03 7.44E-02
PID_AR_TF_PATHWAY 4 3.64E-03 7.44E-02
BIOCARTA_IGF1R_PATHWAY 3 4.07E-03 8.07E-02
REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR 3 4.07E-03 8.07E-02
KEGG_ERBB_SIGNALING_PATHWAY 5 4.19E-03 8.07E-02
REACTOME_SIGNALING_BY_SCF_KIT 5 4.61E-03 8.63E-02
REACTOME_SIGNALING_BY_ERBB4 5 4.61E-03 8.63E-02
REACTOME_UNFOLDED_PROTEIN_RESPONSE 4 4.74E-03 8.76E-02
BIOCARTA_WNT_PATHWAY 3 6.04E-03 9.36E-02
BIOCARTA_BAD_PATHWAY 3 6.04E-03 9.36E-02
BIOCARTA_IGF1MTOR_PATHWAY 3 6.04E-03 9.36E-02
PID_AURORA_A_PATHWAY 3 6.04E-03 9.36E-02
WNT_SIGNALING 4 6.05E-03 9.36E-02
PID_AR_PATHWAY 4 6.79E-03 0.10
REACTOME_SIGNALLING_BY_NGF 7 7.50E-03 0.10